- Home
- KOPN vs CRDF Comparison
KOPN vs CRDF Comparison
Compare KOPN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- CRDF
- Stock Information
- Founded
- KOPN 1984
- CRDF 1999
- Country
- KOPN United States
- CRDF United States
- Employees
- KOPN N/A
- CRDF N/A
- Industry
- KOPN Semiconductors
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOPN Technology
- CRDF Health Care
- Exchange
- KOPN Nasdaq
- CRDF Nasdaq
- Market Cap
- KOPN 282.1M
- CRDF 288.7M
- IPO Year
- KOPN 1992
- CRDF N/A
- Fundamental
- Price
- KOPN $1.38
- CRDF $3.83
- Analyst Decision
- KOPN Strong Buy
- CRDF Strong Buy
- Analyst Count
- KOPN 4
- CRDF 4
- Target Price
- KOPN $2.63
- CRDF $12.00
- AVG Volume (30 Days)
- KOPN 2.3M
- CRDF 1.1M
- Earning Date
- KOPN 05-13-2025
- CRDF 05-01-2025
- Dividend Yield
- KOPN N/A
- CRDF N/A
- EPS Growth
- KOPN N/A
- CRDF N/A
- EPS
- KOPN N/A
- CRDF N/A
- Revenue
- KOPN $44,266,305.00
- CRDF $683,000.00
- Revenue This Year
- KOPN $21.20
- CRDF N/A
- Revenue Next Year
- KOPN $13.55
- CRDF N/A
- P/E Ratio
- KOPN N/A
- CRDF N/A
- Revenue Growth
- KOPN 0.60
- CRDF 39.96
- 52 Week Low
- KOPN $0.56
- CRDF $2.01
- 52 Week High
- KOPN $2.17
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- KOPN 47.23
- CRDF 43.91
- Support Level
- KOPN $1.32
- CRDF $3.52
- Resistance Level
- KOPN $1.48
- CRDF $4.42
- Average True Range (ATR)
- KOPN 0.12
- CRDF 0.29
- MACD
- KOPN 0.01
- CRDF -0.04
- Stochastic Oscillator
- KOPN 64.71
- CRDF 18.89
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").